

Hitachi and Gencurix enter into partnership to expand cancer molecular diagnostics biz in Japan

29 August 2024 | News

Providing new value in cancer diagnosis with synergy of biomarker discovery and digital technology



Japanese firm Hitachi High-Tech Corporation and Korea-based Gencurix, Inc. have entered a strategic partnership in the field of cancer molecular diagnostics.

The partnership aims to develop a testing service for the cancer molecular diagnostics by combining Hitachi High-Tech's core expertise in R&D and manufacturing of in vitro diagnostic products and digital technology, and Gencurix's technology and experience in biomarker discovery for cancer diagnosis and development of molecular testing service.

As a part of the partnership, both companies concluded a Feasibility Study (FS) agreement to examine the feasibility of the business and completed the checkpoints defined in this FS agreement in June 2024. As the next step, Hitachi High-Tech and Gencurix are planning commercialisation of testing services in Japan.

In April 2024, Hitachi, Ltd. and Hitachi High-Tech consolidated Hitachi's Healthcare Business Division (radiation therapy, digital healthcare, etc.) to Hitachi High-Tech to promote the healthcare business based on "Diagnosis x Therapy x Digital" and create healthcare innovation. This partnership is part of Hitachi High Tech's growth strategy of strengthening this molecular diagnostics business.

Hitachi High-Tech and Gencurix will jointly develop cancer diagnostic tests required in clinical practice to promote personalised medicine in the oncology field and aim to provide highly reliable testing service solutions using digital technology. They will first jointly launch a testing service business in Japan and then in other countries.